Abstract:Highlights • The crosstalk between the gut and the brain serves as a route for the spread of PD pathology in a bottom-up or top-down manner. • Gut dysbiosis is evident in PD patients and animal models and is associated with alterations in gut-derived microbial products and immune pathways promoting disease pathology. • Diet induces changes in the GM, with western diet evoking and Mediterranean diet preventing neuroinflammation and neurodegeneration associated with PD. • Gut-derived microbial products can be involved in the regulation of the immune system, the inflammation of both the intestine and the brain, and the integrity of intestinal epithelium and blood-brain barrier (BBB). • Therapeutic strategies that function by reversing gut dysbiosis and mitochondrial dysfunction may prove beneficial to treat PD pathology. Background Parkinson's disease (PD) is a disease of ⍺-synuclein aggregation-mediated dopaminergic neuronal loss in the substantia nigra pars compacta, which leads to motor and non-motor symptoms. Through the last two decades of research, there has been growing consensus that inflammation-mediated oxidative stress, mitochondrial dysfunction, and cytokine-induced toxicity are mainly involved in neuronal damage and loss associated with PD. However, it remains unclear how these mechanisms relate to sporadic PD, a more common form of PD. Both enteric and central nervous systems have been implicated in the pathogenesis of sporadic PD, thus highlighting the crosstalk between the gut and brain. Aim of Review: In this review, we summarize how the alterations in the gut microbiome can affect PD pathogenesis. We highlight various mechanisms increasing/decreasing the risk of PD development. Based on the previous supporting evidence, we suggest how early interventions could protect against PD development and how controlling specific factors, including our diet, could modify our perspective on disease mechanisms and therapeutics. We explain the strong relationship between the gut microbiota and the brain in PD subjects, by delineating the multiple mechanisms involved in neuroinflammation and oxidative stress. We conclude that the neurodetrimental effects of western diet (WD) and the neuroprotective effects of Mediterranean diets should be further explored in humans through clinical trials. Key Scientific Concepts of Review : Alterations in the gut microbiome and associated metabolites may contribute to pathogenesis in PD. In some studies, probiotics have been shown to exert anti-oxidative effects in PD via improved mitochondrial dynamics and homeostasis, thus reducing PD-related consequences. However, there is a significant unmet need for randomized clinical trials to investigate the effectiveness of microbial products, probiotic-based supplementation, and dietary intervention in reversing gut microbial dysbiosis in PD. Graphical abstract Download : Download high-res image (51KB) Download : Download full-size image

PARK7/DJ-1 as a Therapeutic Target in Gut-Brain Axis Diseases

Gut brain axis: an insight into microbiota role in Parkinson’s disease

PARK7/DJ-1 in microglia: implications in Parkinson's disease and relevance as a therapeutic target

DJ-1 (Park7) affects the gut microbiome, metabolites and the development of innate lymphoid cells (ILCs)

DJ-1 (Park7) affects the gut microbiome, metabolites and development of Innate Lymphoid cells (ILCs)

Gut-Brain Axis a Key Player to Control Gut Dysbiosis in Neurological Diseases

Neuroimmune Connectomes in the Gut and Their Implications in Parkinson's Disease

The microbiome–gut–brain axis in Parkinson disease — from basic research to the clinic

The Gut–Brain Axis and Its Relation to Parkinson’s Disease: A Review

Oral, Nasal, and Gut Microbiota in Parkinson's Disease.

Microbiota- Brain-Gut-Axis Relevance to Parkinson's Disease: Potential Therapeutic Effects of Probiotics

Gut microbiome and Parkinson's disease: Perspective on Pathogenesis and Treatment

Microbiota-Brain-Gut Axis and Neurodegenerative Diseases

PARK7/DJ-1 deficiency impairs microglial activation in response to LPS-induced inflammation

Parkinson's disease and gut microbiota: from clinical to mechanistic and therapeutic studies

Gut Microbiota: A Novel Therapeutic Target for Parkinson's Disease

Gut Microbiota and Immune System Dynamics in Parkinson's and Alzheimer's Diseases

The Gut-Brain Axis: Two Ways Signaling in Parkinson’s Disease

The Role of the Gut Microbiota in the Pathogenesis of Parkinson's Disease

Emerging insights between gut microbiome dysbiosis and Parkinson’s disease: Pathogenic and clinical relevance